Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
Pharma significant Lupin on Thursday said that its office in Vizag, Andhra Pradesh, has gotten the examination conclusion report from the US wellbeing controller.
The review for the office was led by the United States Food and Drug Administration (USFDA) during January 13-17, the organization said.
It educated stock trades regarding “the receipt of the foundation review report (EIR) from the United States Food and Drug Administration (USFDA) after conclusion of the examination for its Vizag (Vishakhapatnam), India office.”
“We stay focused on improving consistence and quality gauges at the Vizag office and over the entirety of our assembling locales,” Nilesh Gupta, Managing Director, Lupin said.
The organization’s offers were exchanging at Rs 848 each on BSE in morning exchange, 0.98 percent from the past close.